Patents Examined by Ekaterina Poliakova
  • Beta catenin nucleic acid inhibitor molecule
    Patent number: 11008571
    Abstract: Provided herein is a potent, optimized ?-catenin nucleic acid inhibitor molecule with a unique pattern of modified nucleotides. Also provided are methods and compositions for reducing ?-catenin expression and methods and compositions for treating cancer.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: May 18, 2021
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventor: Shanthi Ganesh
  • Aptamers, nucleic acid molecules, polynucleotides, synthetic antibodies compositions for detecting PRRS viruses and treating PRRS virus infection
    Patent number: 11001846
    Abstract: Aptamers, polynucleotides which participate in preventing the Porcine Respiratory and Reproductive Syndrome virus (PRRSV) infection of cells, and nucleic acid molecules, which include a polynucleotide sequence capable of specifically binding the polypeptides domain of the PRRSV that controls infection, constitute the core of the present invention. Also provided are methods of using such nucleic acid molecules, polynucleotides and synthetic antibodies directed against these, for detection, treating and neutralization of PRRSV infection.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: May 11, 2021
    Assignee: AEROVIRUS TECHNOLOGIES INC.
    Inventors: Norman Marchand, Thomas Caltagirone, Albert Liao
  • Functional ligands to lipoarabinomannan
    Patent number: 10941444
    Abstract: The present invention relates functional ligands to target molecules, particularly to functional nucleic acids and modifications thereof, and to methods for simultaneously generating, for example, numerous different functional biomolecules, particularly to methods for generating numerous different functional nucleic acids against multiple target molecules simultaneously. The present invention further relates to functional ligands which bind with affinity to target molecules, such as lipoarabinomannan (LAM).
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: March 9, 2021
    Assignee: Base Pair Biotechnologies, Inc.
    Inventors: George W. Jackson, Robert Batchelor, Rafal Drabek, Caitlin Bruns
  • Therapeutic oligonucleotides
    Patent number: 10941176
    Abstract: Methods and compositions are provided for oligonucleotides that bind targets of interest. The targets include cells and microvesicles, such as those derived from various diseases. The oligonucleotides can be used for diagnostic and therapeutic purposes. The target of the oligonucleotides can be a target such as PARP1, HIST1H1B, HIST1H1D, NCL, FBL, SFPQ, RPL12, ACTB, HIST1H4A, SSBP1, NONO, H2AFJ, and DDX21, or a complex, subunit or fragment thereof.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: March 9, 2021
    Assignee: Caris Science, Inc.
    Inventors: Heather O'Neill, Günter Mayer, Mark Miglarese, David Spetzler
  • Treatment of Sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a Sirtuin (SIRT)
    Patent number: 10934546
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Sirtuin (SIRT), in particular, by targeting natural antisense polynucleotides of a Sirtuin (SIRT). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Sirtuins (SIRT)s.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: March 2, 2021
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • Antisense oligonucleotide for splicing adjustment of mutant dopa decarboxylase gene and using method thereof
    Patent number: 10920225
    Abstract: This present invention discloses an antisense oligonucleotide for splicing adjustment of mutant dopa decarboxylase gene which is complementary to SEQ ID NO: 1. This antisense oligonucleotide can modulate alternative splicing site of mutant dopa decarboxylase gene. It is helpful to research and develop drug to treat AADC deficiency symptom. This present invention also discloses a method to use said antisense oligonucleotide in vitro.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: February 16, 2021
    Assignee: TAICHUNG VETERANS GENERAL HOSPITAL
    Inventors: Chi-Ren Tsai, Ching-Shiang Chi, Hsiu-Fen Lee
  • Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
    Patent number: 10920227
    Abstract: The present invention relates to small interfering RNA (siRNA) molecules against the SOD1 gene, adeno-associated viral (AAV) vectors encoding siRNA molecules and methods for treating amyotrophic lateral sclerosis (ALS) using the siRNA molecules and AAV vectors.
    Type: Grant
    Filed: January 28, 2020
    Date of Patent: February 16, 2021
    Assignee: VOYAGER THERAPEUTICS, INC.
    Inventors: Dinah Wen-Yee Sah, Jinzhao Hou, Mathieu E. Nonnenmacher, Pengcheng Zhou, Markus Hossbach, Jochen Deckert
  • Functional ligands to biocides
    Patent number: 10920228
    Abstract: The present invention relates functional ligands to target molecules, particularly to functional nucleic acids and modifications thereof, and to methods for simultaneously generating, for example, numerous different functional biomolecules, particularly to methods for generating numerous different functional nucleic acids against multiple target molecules simultaneously. The present invention further relates to functional ligands which bind with affinity to target molecules, such as biocide molecules.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: February 16, 2021
    Assignee: Base Pair Biotechnologies, Inc.
    Inventors: George W. Jackson, Robert Batchelor, Alexander S. Chiu, Rafal Drabek, Deepak Thirunavukarasu
  • Treatment of heart disease by inhibtion of the action of muscle A-kinase anchoring protein (mAKAP)
    Patent number: 10907153
    Abstract: The present invention provides a method of protecting the heart from damage, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the interaction of RSK3 and mAKAP?, or the expression or activity of one or both of those molecules. This composition is preferably in the form of an siRNA construct, more preferably an shRNA construct, which inhibits the expression of mAKAP?.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: February 2, 2021
    Inventor: Michael S. Kapiloff
  • Methods and compositions for treating a premature stop codon-mediated disorder
    Patent number: 10905778
    Abstract: Modified tRNAs can be used to express in a mammalian cell a functional gene product encoded by a gene containing a premature stop codon and/or to treat a disease mediated by a premature stop codon.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: February 2, 2021
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Jeffery M. Coller, Thomas Sweet
  • Aptamers that bind to natural and synthetic cannabinoids
    Patent number: 10907163
    Abstract: The subject invention provides materials and methods for single-step detection of small molecules, e.g., natural and synthetic cannabinoids, in a sample. The subjection invention provides nucleic acids materials, e.g., aptamers (nucleic acid oligonucleotides) that can bind to natural and/or synthetic cannabinoids. The method for detecting a natural or synthetic cannabinoid in a sample comprises contacting the sample with an aptamer-based sensor selective for the natural or synthetic cannabinoid, and sensitively and rapidly detecting the natural or synthetic cannabinoid in the sample. The aptamer-based sensor comprises aptamers that can specifically binds to natural and/or synthetic cannabinoids with nanomolar dissociation constant.
    Type: Grant
    Filed: June 15, 2020
    Date of Patent: February 2, 2021
    Assignee: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES
    Inventors: Yi Xiao, Haixiang Yu
  • Control of coleopteran pests using RNA molecules
    Patent number: 10898507
    Abstract: Disclosed are double stranded RNA molecules that are toxic to coleopteran insects. In particular, interfering RNA molecules capable of interfering with pest target genes and that are toxic to the target pest are provided. Further, methods of making and using the interfering RNA, for example in transgenic plants or as the active ingredient in a composition, to confer protection from insect damage are disclosed.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: January 26, 2021
    Assignee: SYNGENTA PARTICIPATIONS AG
    Inventors: Kevin V. Donohue, Yann Naudet, Pascale Feldmann, Lies Degrave, Isabelle Maillet
  • Methods and compositions to inhibit metastasis and to treat fibrosis and to enhance wound healing
    Patent number: 10894961
    Abstract: Methods and compositions are provided for inhibiting or treating metastasis based on discoveries regarding Kif19 and Cep192. Methods and compositions are provided for enhancing wound healing, treating fibrosis, reducing scarring and treating nerve pain.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: January 19, 2021
    Inventors: David Sharp, Brian O'Rourke
  • Oligonucleotide therapy for Leber Congenital Amaurosis
    Patent number: 10889817
    Abstract: Antisense oligonucleotides target the mutation in intron 26 of the CEP290 gene and reduce inclusion of the aberrant exon into the CEP290 mRNA. The oligonucleotides include no more than 3 consecutive guanosines, have no more than 60% guanosine nucleobases, include at most one CpG sequence, and/or do not have the potential to form a hairpin comprising 3 or more consecutive complementary base pairs.
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: January 12, 2021
    Assignee: ProQR Therapeutics II B.V.
    Inventors: Patricia Coromoto Biasutto, Hee Lam Chan
  • Monocarboxylate transporter 4 (MCT) antisense oligonucleotide (ASO) inhibitors for use as therapeutics in the treatment of cancer
    Patent number: 10889814
    Abstract: Provided herein are compositions, method and uses for modulating MCT4 activity or for the treatment of cancer. The compositions comprise antisense oligonucleotides (ASO) for administration to a cancer cell, wherein the cancer cell may be characterized by elevated expression of MCT4. The cancer may be selected from one or more of: prostate cancer; renal cell carcinoma; breast cancer; cervical cancer; liver cancer; bladder cancer; and small cell lung cancer pr. The prostate cancer may be castration-resistant prostate cancer (CRPC).
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: January 12, 2021
    Inventors: Yuzhuo Wang, Stephen Yiu Chuen Choi
  • Extracellular vesicles derived from osteoblastic lineage cells for therapeutic and diagnostic use
    Patent number: 10881611
    Abstract: The present invention relates to RANKL+ cellular vesicles isolated from osteoblastic lineage cells, optionally immortalised, their use for the therapeutic treatment of bone pathologies and for diagnostic purposes, and processes for the production of said vesicles.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: January 5, 2021
    Assignee: Fondazione Città Della Speranza—Onlus
    Inventors: Maurizio Muraca, Alfredo Cappariello, Anna Maria Teti
  • Inhibitory RNA-based therapeutics targeting ANLN for cancer treatment
    Patent number: 10870854
    Abstract: Embodiments of the present disclosure include compositions and methods related to certain siRNA compositions for the treatment of cancer. In specific embodiments, siRNAs are employed for treatment of cancer, including at least liver cancer. Therapeutic methods, compositions, and kits are encompassed in the disclosure.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: December 22, 2020
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Hao Zhu, Shuyuan Zhang
  • Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder
    Patent number: 10851377
    Abstract: The invention relates to methods of inhibiting the expression of a PCSK9 gene in a subject, as well as therapeutic and prophylactic methods for treating subjects having a lipid disorder, such as a hyperlipidemia using RNAi agents, e.g., double-stranded RNAi agents, targeting the PCSK9 gene.
    Type: Grant
    Filed: January 16, 2020
    Date of Patent: December 1, 2020
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventor: Kevin Fitzgerald
  • Aptamer biosensors useful for detecting hormones, hormone mimics, and metabolites thereof
    Patent number: 10844386
    Abstract: The present invention provides polynucleotides that bind to small molecules and methods of using the polynucleotides. In some embodiments, a method comprises detecting a small molecule with a polynucleotide. In other embodiments, a method comprises administering a polynucleotide to inhibit the action of a small molecule. In some embodiments, the small molecule is a hormone, a hormone mimic, phytoestrogen, opiate, opioid, endocrine disrupting compound, metabolite thereof, or variant thereof.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: November 24, 2020
    Assignee: AURAMER BIO LIMITED
    Inventors: Shalen Kumar, Kenneth McNatty
  • Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA
    Patent number: 10844381
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing ?-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: November 24, 2020
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek